The Netherlands: BioGeneration Ventures closes BGV Fund V at €150m

Edward van Wezel, managing partner at BGV © Joost van Manen

BioGeneration Ventures (BGV), an early-stage VC in European biopharma, has closed BGV V at €150m (US$167m), its largest fund since launching its first in 2006. BGV V was said to be oversubscribed, having attracted demand from both existing investors – including Eli Lilly, Novo Holdings and Bristol Myers Squibb – and new investors. Some 78%…

You must be a HMI Subscriber to view this content.

Subscribe Now »